Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities.
The effects of viloxazine, a clinically effective antidepressant, on noradrenaline (NA) and 5-hydroxytryptamine (5-HT) uptake and various related pharmacological activities were determined and compared to those of the tricyclic antidepressants desimipramine, imipramine, and amitriptyline. Viloxazine inhibitied [3H]NA uptake in the mouse and rat heart, being maximally about one half as potent as imipramine with a similar onset, but shorter duration of action than imipramine. The drug did not inhibit [3H]NA uptake in rat medulla or hypothalamus in contrast to desimipramine and imipramine, but it did alter [3H]NA metabolites in a similar manner. Viloxazine, like desimipramine, was a weak blocker of mouse brain 5-HT uptake, but differed from desimipramine as it poteniated 5-HT-mediated functions in the mouse and rat, as did imipramine and amitriptyline, the latter drugs being relatively potent blockers of 5-HT uptake. Viloxazine potentiated the L-DOPA behavioural syndrome in the mouse, antagonized reserpine-induced ptosis and hypothermia in the mouse, and inhibited gastric acid secretion in the rat, but was less potent than the tricyclic antidepressants. No appreciable in vivo inhibition of monoamine oxidase (EC 1.4.3.4.) activity in the mouse was exhibited. Like imipramine, the drug potentiated the ocular effects of L-adrenaline in the rabbit. It was similar to imipramine in potency in potentiating the apomorphine-induced gnawing in the mouse. The drug antagonized oxotremorine-induced hypothermia in the mouse but differed from the tricyclic antidepressants in not exhibiting the anticholinergic effects of blocking the tremors, salivation and lacrimation. Thus, viloxazine exhibits activities related to the biogenic amines both similar to and different from the tricyclics desimipramine, imipramine, and amitriptyline. These actions appear to be of relevance with respect to the antidepressant action of this drug.
D000639:Amitriptyline / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D003891:Desipramine / Q000494:pharmacology; D004357:Drug Synergism; D005750:Gastric Juice / Q000378:metabolism; D007099:Imipramine / Q000494:pharmacology; D066298:In Vitro Techniques; D007980:Levodopa / Q000494:pharmacology; D051379:Mice; D009025:Morpholines / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D011680:Pupil / Q000187:drug effects; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D014439:Tyramine / Q000031:analogs & derivatives / Q000494:pharmacology; D014745:Viloxazine / Q000494:pharmacology*
D001679:Biogenic Amines; D009025:Morpholines; D000639:Amitriptyline; D012701:Serotonin; D007980:Levodopa; D014745:Viloxazine; D010095:Oxotremorine; D012110:Reserpine; D001058:Apomorphine; D007099:Imipramine; D003891:Desipramine; D009638:Norepinephrine; D014439:Tyramine